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Abstract
Background: It is believed that animal-to-human transmission of severe acute respiratory syndrome
(SARS) coronavirus (CoV) is the cause of the SARS outbreak worldwide. The spike (S) protein is one of
the best characterized proteins of SARS-CoV, which plays a key role in SARS-CoV overcoming species
barrier and accomplishing interspecies transmission from animals to humans, suggesting that it may be the
major target of selective pressure. However, the process of adaptive evolution of S protein and the exact
positively selected sites associated with this process remain unknown.
Results: By investigating the adaptive evolution of S protein, we identified twelve amino acid sites (75,
239, 244, 311, 479, 609, 613, 743, 765, 778, 1148, and 1163) in the S protein under positive selective
pressure. Based on phylogenetic tree and epidemiological investigation, SARS outbreak was divided into
three epidemic groups: 02–04 interspecies, 03-early-mid, and 03-late epidemic groups in the present study.
Positive selection was detected in the first two groups, which represent the course of SARS-CoV
interspecies transmission and of viral adaptation to human host, respectively. In contrast, purifying
selection was detected in 03-late group. These indicate that S protein experiences variable positive
selective pressures before reaching stabilization. A total of 25 sites in 02–04 interspecies epidemic group
and 16 sites in 03-early-mid epidemic group were identified under positive selection. The identified sites
were different between these two groups except for site 239, which suggests that positively selected sites
are changeable between groups. Moreover, it was showed that a larger proportion (24%) of positively
selected sites was located in receptor-binding domain (RBD) than in heptad repeat (HR)1-HR2 region in
02–04 interspecies epidemic group (p = 0.0208), and a greater percentage (25%) of these sites occurred
in HR1–HR2 region than in RBD in 03-early-mid epidemic group (p = 0.0721). These suggest that
functionally different domains of S protein may not experience same positive selection in each epidemic
group. In addition, three specific replacements (F360S, T487S and L665S) were only found between 03-
human SARS-CoVs and strains from 02–04 interspecies epidemic group, which reveals that selective
sweep may also force the evolution of S genes before the jump of SARS-CoVs into human hosts. Since
certain residues at these positively selected sites are associated with receptor recognition and/or
membrane fusion, they are likely to be the crucial residues for animal-to-human transmission of SARS-
CoVs, and subsequent adaptation to human hosts.
Conclusion: The variation of positive selective pressures and positively selected sites are likely to
contribute to the adaptive evolution of S protein from animals to humans.
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Background
SARS is a new infectious disease that emerged in the
Guangdong province of China in November 2002. It
caused 8,096 infection cases including 774 deaths world-
wide during its epidemic [1]. The causative pathogen of
SARS was identified as a novel strain of human coronavi-
rus, named as SARS-CoV, and its complete genome was
sequenced in March 2003 [2-5]. In May 2003, SARS-CoVs
were also isolated from a few Himalayan palm civets
(Paguma larvata) and a raccoon dog (Nyctereutes procyo-
noides) in a food market in Shenzhen (Guangdong,
China) [6]. These isolations provided the first evidence
that wild animals could be reservoirs for SARS-CoV, and
that the virus might be transmitted from animals to
humans. The re-emergence of SARS in 2003–2004 in
Guangdong, China confirmed that SARS-CoV was inde-
pendently transmitted from animals to humans [7].
The S protein of SARS-CoV is composed of 1,255 amino
acids, and is responsible for viral attachment and entry
into host cells [4,5]. It is also a major antigenic determi-
nant that induces generation of neutralizing antibodies
and protective immunity at least in human host [8].
Unlike some coronaviruses, in which S protein can be
cleaved into two functional subunits, S1 and S2, the S pro-
tein of SARS-CoV is not cleavable due to the absence of
the proteolytic cleavage site. However, two domains, S1
(residues 14–680) and S2 (residues 681–1,255) were
identified in SARS-CoV S protein in the light of their
homology with the S1 and S2 subunits [9]. Domain S1 is
responsible for binding to angiotensin-converting
enzyme-2 (ACE2), which serves as the functional receptor
of SARS-CoV [10,11]. Domain S2 mediates viral entry into
host cells [12,13]. Previous works indicated that interspe-
cies transmission may be due to the acquisition of muta-
tions in S protein which allows human infection,
suggesting that S protein ought to be a major target of
selective pressure [6,7,14].
A criterion for the determination of selective pressure is to
compare nonsynonymous (amino acid-changing; dN)
with synonymous (silent; dS) substitution rates in protein-
coding genes. The nonsynonymous/synonymous rate
ratio (ω = dN/dS) provides a straightforward measurement
of selective pressure at the protein level. The ω values of >
1, 1 and < 1 indicate positive (diversifying) selection, ran-
dom drift and negative (purifying) selection, respectively.
The pairwise analysis showed that S protein, which has an
average ω ratio for all amino acid sites greater than 1, is
under overall positive selective pressure [7,14,15]. How-
ever, the process of adaptation of S protein to human
receptors and the positively selected sites associated with
this process remain unclear. Because previous epidemic
phases [7,14] are unable to adequately reflect the process
of animal-to-human transmission and of viral adaptation
to human host, we therefore reclassified the SARS groups
in the present study. We found that the S protein of SARS-
CoV experiences variable positive selective pressures and
the positively selected sites are changeable in different epi-
demic groups. These observations provide a good evi-
dence for understanding the molecular adaptation of
SARS-CoV from animals to humans.
Results
Positive selection on S genes of SARS-CoV during the whole 
outbreak from 2002 to 2004
The likelihood values and parameter estimates of 45 S
gene sequences from six models implemented in program
Codeml are listed in Table 1. The average ω values ranged
from 0.36 to 0.69 among all models, showing the evi-
dence of purifying selection. Although the one-ratio
model (M0) showed that all sites of S gene have a ω ratio
of 0.64, it was easily rejected as a result of the lowest like-
lihood value (-5818.14) and the likelihood ratio test
(LRT) statistic (2 delta lambda statistic, 2Δl) (Table 1).
Three models (M2a, M3 and M8) that allow for selection
indicated the presence of 5.2–5.9% positively selected
Table 1: Likelihood values and parameter estimates for 45 S gene sequences from the whole epidemic of SARS from 2002 to 2004.
Model code lnL dN/dS Estimates of parameters 2Δl Positively selected sites
M0 (one-ratio) -5818.14 0.64 ω = 0.64 51.91 None
M3 (discrete) -5792.19 0.69 p0 = 0.43340, p1 = 0.50712 (p2 = 0.05948), ω0 = 0.12, 
ω1 = 0.13, ω2 = 9.68
(13.28) 75T 239S 244T 311G 479R 609L 
613E 743R 765V 778D 1148L 
1163E
M1a (NearlyNeutral) -5807.78 0.36 p0 = 0.63944 (p1 = 0.36056) 31.25 Not allowed
M2a (PositiveSelection) -5792.16 0.69 p0 = 0.78594, p1 = 0.16251 (p2 = 0.05155), ω2 = 
10.29
(9.21) 75T 239S 244T 311G 479R 609L 
613E 743R 765V 778D 1148L 1163E
M7 (beta) -5807.92 0.40 p = 0.00568, q = 0.00856 31.51 Not allowed
M8 (beta&v) -5792.16 0.69 p0 = 0.94614 (p1 = 0.05386)
p = 0.05787, q = 0.30879, ω = 10.11
(9.21) 75T 239S 244T 311G 479R 609L 
613E 743R 765V 778D 1148L 
1163E
The values in parentheses represent the significant level of 0.01 with a χ2distribution at d.f. = 4 (M0 vs. M3) or 2 (M1a vs. M2a and M7 vs. M8). The 
amino acid sequence of strain PC4-13 was used as the sequence reference, and positive selected sites were identified with posterior probability p ≥ 
0.9. In boldface, p ≥ 0.95.BMC Microbiology 2006, 6:88 http://www.biomedcentral.com/1471-2180/6/88
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sites with similar ω values (9.68–10.29). LRT statistic
showed that the three selection models fitted the data sig-
nificantly better than the null models without selection,
supporting the presence of 5.2–5.9% amino acid sites of S
gene under strong positive selection (Table 1). At the level
of posterior probability > 0.95, four, twelve and eight sites
of S protein were identified to be under positive selection
(ω > 1) by selection models M2a, M3 and M8, respectively
(Table 1). Twelve positively selected sites detected by M3
were also identified by M2a and M8 at the level of poste-
rior probability > 0.9 (Table 1). The number of positively
selected sites discovered in the present study was similar
to the number of the sites identified in previous reports
[16, 17].
Detection of recombination and positive selection on S 
genes of SARS-CoV in different epidemic groups
Recombination can influence the detection of positive
selection [18,19], and previous studies had proposed that
recombination occurs in the origin of SARS-CoV [20]. In
02–04 interspecies epidemic group, human sequence
GZ03-02 split 03-pcSARS-CoVs from 04-pcSARS-CoVs,
whereas other 04-huSARS-CoVs clustered with 04-
pcSARS-CoVs (Fig. 1), suggesting that GZ03-02 may be a
recombinant between 03-pcSARS-CoVs and 04-pcSARS-
CoVs. However, the bootscan analysis of GZ03-02 using
SimPlot software showed that majority of GZ03-02 S gene
had the percent of permuted trees less than 40 (Fig. S1, see
additional file 1), indicating that they possess similar
identity to other sequences, and suggesting that no recom-
bination occurred in this strain [21]. In addition, viral
recombination requires the co-infection of different virus
strains [22], and there was little chance for GZ03-02
patients to be co-infected with 03-pcSARS-CoV and 04-
pcSARS-CoV during 2004 epidemic [7], further support-
ing the view that no recombination occurred in S gene of
GZ03-02 [21].
Three selection models (M2a, M3 and M8) showed that
positive selection occurred in both 02–04 interspecies and
03-early-mid epidemic groups (Table 2). For instance, M8
showed that 0.6% of the sites in 02–04 interspecies epi-
demic group were under positive selection with ω values
between 66.0–67.2, and 2.7% of the sites in 03-early-mid
epidemic group were under positive selection with ω =
40.9. LRT statistic revealed that three selection models fit-
ted the data better than three null models in both groups
of 02–04 interspecies epidemic and 03-early-mid epi-
demic, which supports further the presence of amino acid
sites under positive selection in S protein (Table 2). In
contrast, we were unable to identify any site under posi-
tive selection with any of the six models in the 03-late epi-
demic group. Instead, the results for this group were
consistent with purifying selection (with ω values of 0.25–
0.26) (Table 2).
Comparison of positively selected sites on S genes in 
different epidemic groups
The positively selected sites in both groups of 02–04 inter-
species epidemic and 03-early-mid epidemic were identi-
fied using Codeml program. Although three selection
models: M2a, M3 and M8 detected same positively
selected sites on S genes, only the results from M8 are
shown in Table 3. Four positively selected sites (479, 609,
743, and 765) in 02–04 interspecies epidemic group and
four sites (75, 239, 778 and 1163) in 03-early-mid epi-
demic group were identified at the level of posterior prob-
ability > 0.95, respectively. In addition, 25 and 16 sites
were detected under positive selection (ω > 1) in 02–04
interspecies epidemic and 03-early-mid epidemic groups
at the level of posterior probability > 0.50, respectively. By
REL method, completely identical 25 sites in 02–04 inter-
species epidemic group and 16 sites in 03-early-mid epi-
demic group were identified under positive selection at
significant level of Bayes factor > 50 (Table 3). When FEL
and SLAC methods were used, these sites were also iden-
Phylogenetic tree of 47 S gene sequences from human  patients and animals Figure 1
Phylogenetic tree of 47 S gene sequences from 
human patients and animals. The evolutionary process 
of S proteins during whole epidemic was simplified into three 
epidemic groups: 02–04 interspecies, 03-early-mid, and 03-
late epidemic groups. Each group includes 15 unique S gene 
sequences after deleting all duplicate sequences (Table S1, 
see additional file 2). Two sequences isolated from bats were 
used as the outgroup in phylogenetic tree construction. The 
tree was constructed by the maximum likelihood method 
with 1000 bootstrap replicates using PHYML v2.4.4. Only the 
branch bootstrap values ≥ 50% are shown. PC, palm civet; 
HP, human patient.BMC Microbiology 2006, 6:88 http://www.biomedcentral.com/1471-2180/6/88
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tified under positive selection in despite of not reaching
the significant level of p < 0.1. No positively selected site
was identified in 03-late epidemic group by three selec-
tion models (even at the level of posterior probability >
0.50) implemented in Codeml program and three meth-
ods implemented in DataMonkey package (Table 3), indi-
cating that this group was experiencing purifying
selection.
In order to investigate the association of positively
selected sites with the function of S protein, we compared
their location between groups of 02–04 interspecies epi-
demic and 03-early-mid epidemic. The results show that
apart from the site 239, the two groups had completely
different sites (Table 3), suggesting for the first time that
positively selected sites are variable in different epidemic
groups. It was found that 72% (18 out of 25) positively
selected sites in 02–04 interspecies epidemic group were
located in S1 domain, which is greater than 50% (8 out of
16) of that located in S1 domain in 03-early-mid epi-
demic group (p = 0.0768) (Table 3). Moreover, 24% of
positively selected sites in 02–04 interspecies epidemic
group were concentrated in the region of receptor-binding
domain (RBD), only 4% in heptad repeat (HR)1-HR2
region (p = 0.0208), but 0% in HR2 region (p = 0.0045).
Contrarily, 25% of positively selected sites in 03-early-
mid epidemic group were concentrated in HR1–HR2
region (p = 0.0721), 18.8% in HR2 region (p = 0.1425),
but only 6.3% in RBD region (Table 3 and 4). These
results suggest that positive selection tends to selectively
influence certain functions of S protein, but not others in
each epidemic group.
Lineage fixation of positively selected sites on S genes for 
the adaptation of SARS-CoV to human host
Four positively selected sites (479, 609, 743 and 765)
identified in 02–04 interspecies epidemic group were
fixed in 03-early-mid epidemic group (Fig. 2). The 04-
Table 2: Phylogenetic analysis by ML estimation for SARS S gene sequences from different epidemic groups.
Epidemic phases Model code lnL dN/dS Estimates of parameters 2Δl Positive 
selection
02–04 interspecies 
epidemic group
M0 (one-ratio) -5339.90 0.64 ω = 0.64 40.23 Yes
M3 (discrete) -5319.78 0.77 p0 = 0.00000, = p1 = 0.99407 (p2 = 0.00593), ω0 
= 0.00, ω1 = 0.38, ω2 = 66.02
(13.28)
M1a (NearlyNeutral) -5334.74 0.35 p0 = 0.65391 (p1 = 0.34609) 29.92 Yes
M2a (PositiveSelection) -5319.78 0.77 p0 = 0.99407, p1 = 0.00000 (p2 = 0.00593), ω2 = 
66.01
(9.21)
M7 (beta) -5336.08 0.30 p = 0.01702, q = 0.03977 32.23 Yes
M8 (beta&v) -5319.97 0.80 p0 = 0.99405 (p1 = 0.00595), p0 = 0.01217, q = 
0.01714 ω = 67.24
(9.21)
03-early-mid epidemic 
group
M0 (one-ratio) -5194.47 0.94 ω = 0.94 24.25 Yes
M3 (discrete) -5182.34 1.10 p0 = 0.05053, p1 = 0.92251 (p2 = 0.02696), ω0 = 
ω1 = 0.00, ω2 = 40.88
(13.28)
M1a (NearlyNeutral) -5192.6 9 0.45 p0 = 0.54981 (p1 = 0.45019) 20.70 Yes
M2a (PositiveSelection) -5182.34 1.10 p0 = 0.97303, p1 = 0.00000 (p2 = 0.02696), ω2 = 
40.88
(9.21)
M7 (beta) -5192.73 0.40 p = 0.00510, q = 0.00776 20.78 Yes
M8 (beta&v) -5182.34 1.10 p0 = 0.97303 (p1 = 0.02697), p = 0.00500, q = 
1.39962, ω = 40.87
(9.21)
03-late epidemic 
group
M0 (one-ratio) -5121.66 0.26 ω = 0.26 NA No
M3 (discrete) -5121.66 0.26 p0 = 0.43056, p1 = 0.37490 (p2 = 0.19455), ω0 = 
0.25, ω1 = 0.26, ω2 = 0.26
(13.28)
M1a (NearlyNeutral) -5121.66 0.26 p0 = 1.00000 (p1 = 0.00000) NA No
M2a (PositiveSelection) -5121.66 0.26 p0 = 1.00000, p1 = 0. 00000 (p2 = 0.00000), ω0 
= 0.26, ω1 = ω2 = 1.00
(9.21)
M7 (beta) -5121.66 0.25 p = 33.88884, q = 99.00000 NA No
M8 (beta&v) -5121.68 0.26 p0 = 1.00000 (p1 = 0.00000), p = 0.64576, q = 
1.83663, ω = 2.08
(9.21)
The values in parentheses represent the significant level of 0.01 with a χ2distribution at d.f. = 4 (M0 vs. M3) or 2 (M1a vs. M2a and M7 vs. M8). NA, 
not applicable.BMC Microbiology 2006, 6:88 http://www.biomedcentral.com/1471-2180/6/88
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pcSARS-CoVs diverged from 03-pcSARS-CoVs after the
split between 03-pcSARS-CoVs and 03-huSARS-CoV (Fig.
1) [7]. The comparison of amino acid sequences between
03-pcSARS-CoV and 03-huSARS-CoV suggested that vari-
ants N479K and T743A play a dominant role in transition
of viral host tropism from animals to humans (Fig. 2). The
comparison between 03-huSARS-CoV and 03-pcSARS-
CoV sequences discovered two additional variants, L609A
and V765A, which may favor viral adaptation to palm
civet. Four sites (75T, 239S, 778Y, and 1163K) identified
under positive selection in the 03-early-mid epidemic
group were fixed in the 03-late epidemic group (Fig. 2).
The fixation of these amino acids suggests that they are
likely to contribute to the adaptation process of S protein
to human receptors.
Discussion
The S protein of SARS-CoV is responsible for the receptor
binding and membrane fusion [10]. It is also a major anti-
gen to stimulate humoral immunity of its host [8]. The
amino acid variation of S protein affects virus entry, tissue
tropism and host range of SARS-CoV [11,23]. Here, we
confirmed that the S gene undergoes strong positive selec-
tion [7,14-16], and identified twelve positively selected
amino acid sites, including 75, 239, 244, 311, 479, 609,
613, 743, 765, 778, 1148, and 1163 during the whole
SARS outbreak (Table 1). Among these sites, positions
239, 311, 479, 609, 743, 778, 1148, and 1163 appeared
to be exposed on the surface of S protein [9,24], suggest-
ing that they are likely to play a key role in viral transmis-
sion and survival. In addition, it was worth pointing out
that SARS-CoV is a rapidly evolving RNA virus with a
mutation rate of 0.8–2.38 × 10-3 nucleotide substitution
per site per year [25]. The S gene sequences used in the
present study were sampled during a year period, and
some mutations might be accumulated in late-sampled
sequences [26,27]. However, whether the accumulation
of these mutations influences the detection of positive
selection and the identification of positively selected sites
remains unclear [26]. This requires further investigation
to confirm.
Adaptation of an animal virus to a new human host usu-
ally faces two crucial bottlenecks: the receptor adaptation
of viral surface protein to its new host, followed by the
adaptation of key enzymes (e.g. viral replicases) associ-
ated with viral replication to new cellular components
that possibly support poorly productive infection (e.g.
non-permissive cells) [21,28]. The latter is not always the
step that limits host expansion and most viruses can
establish productive infection after their entry of host cells
[29]. We found that two key replicases of SARS-CoV, RNA-
dependent RNA polymerase (RdRp) and helicase, were
not under positive selection (Zhang CY et al., unpub-
lished data), which suggests that receptor adaptation of S
protein to human host determines the animal-to-human
transmission of SARS-CoV [11,29]. The receptor adapta-
tion of an animal virus to a new human host usually
requires two key steps: initial breakthrough of receptor
barrier (animal-to-human transmission), followed by the
molecular adaptation to human cellular receptors
(human-to-human transmission). The two steps together
result in eventual establishment of stable infection neces-
sary for efficient spread within human hosts.
In order to better reflect the course of viral trans-species
transmission and subsequent adaptation to human hosts,
the collection of SARS isolates was reclassified into three
epidemic groups: 02–04 interspecies, 03-early-mid, and
03-late epidemic groups in the present study. The 02–04
Table 4: The number of positively selected sites in different functional domains of S protein.
Functional domain 02–04 interspecies epidemic 
group
03-early-mid epidemic group Fisher's exact test (p)
RBD 61
HR1–HR2 1 4 0.045455
HR2 0 3 0.033333
The Fisher's exact test was performed for HR1–HR2 vs. RBD, and HR2 vs. RBD, respectively.
Table 3: Positively selected sites identified by Codeml program and REL in DataMonkey package.
Domains Positively selected sites in different epidemic groups
02–04 interspecies 03-early-mid 03-late
S1 78 113 139 147 227 239 261 336 425 462 472 479 480 558 607 608 609 613 49 75 77 144 239 244 311 344 None
S2 701 714 743 754 765 856 894 778 860 861 1001 1148 1163 1179 1247 None
Positively selected sites identified by program Codeml at the level of posterior probability ≥ 0.95 are shown in boldface. The underlines represent 
the sites locating in receptor-binding domain (RBD) (residues: 318–510) of S1 domain or in heptad repeat (HR)1 (residues: 889–972)-HR2 
(residues: 1142–1185) region of S2 domain.BMC Microbiology 2006, 6:88 http://www.biomedcentral.com/1471-2180/6/88
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interspecies epidemic group reflects the process of viral
trans-species transmission, and 03-early-mid epidemic
group represents the crucial phase of SARS-CoVs to adapt
to human host. The two groups correspond with the two
key steps described above for a virus to be adapted by a
new cellular receptor.
We found that S genes underwent strong positive selection
in both groups of 02–04 interspecies epidemic and 03-
early-mid epidemic, whereas no positive selection was
observed in 03-late epidemic group (Table 2). It suggests
that S protein experiences a step-by-step adaptation proc-
ess to human cellular receptors. On the other hand, the
amino acid sites under positive selection in 02–04 inter-
species epidemic group differed clearly from those in 03-
early-mid epidemic group, suggesting for the first time the
changes in positively selected sites in different epidemic
groups. It was reported previously that two functional
domains S1 and S2 of SARS-CoV S protein are responsible
for receptor recognition and membrane fusion, respec-
tively [10]. In domain S1, RBD has been demonstrated to
concentrate in a 193-amino acid fragment (residues 318–
510), which is adequate for binding to human ACE2 [30].
In domain S2, two highly conserved regions HP1 (resi-
dues: 889–972) and 2 (residues: 1142–1185) are crucial
for membrane fusion [31]. Importantly, a larger propor-
tion of positively selected sites was located in RBD than in
HR1–HR2 or HR2 regions in 02–04 interspecies epidemic
group, and a greater percentage of these sites occurred in
HR1–HR2 region than in RBD in 03-early-mid epidemic
group (Fisher's exact test: p = 0.045 for HR1–HR2 vs. RBD,
and p = 0.033 for HR2 vs. RBD) (Table 4). These differ-
ences suggest that positive selection prefers influencing
the receptor-binding function in 02–04 interspecies epi-
demic group, and then associates with the membrane
fusion function in 03-early-mid epidemic group.
In 02–04 interspecies epidemic group, four positively
selected sites 479, 609, 743 and 765 appeared to be fixed
in 03-early-mid epidemic group. Comparing the amino
acid sequences of S genes from 03-huSARS-CoV and 03-
pcSARS-CoV, we discovered that two positively selected
amino acid substitutions (N479K and T743A) are likely to
play a role in viral receptor switch. Previous in vitro exper-
iments proved that the residues at positions 479 and 487
are important determinants for SARS-CoV cell tropism
and animal-to-human transmission [11,23,32,33]. Resi-
due 479N (asparagine) increases the affinity of S protein
to human receptor by specifically interacting with the res-
idue 34H (histidine) of ACE2, which is present in human
but not in palm civet ACE2 [11,32]. Recently, Zheng et al.
reported that active peptide (residues 737–756) of S pro-
tein which contains residue 743T (threonine) effectively
inhibited the entry of huSARS-CoV into human cells [34].
The corresponding peptide with residue 743A (alanine)
from 03-pcSARS-CoV appeared less potent against
huSARS-CoV [34]. These observations suggested that resi-
due 743 may influence viral receptor tropism via a way
different from ACE2 binding [34]. Besides ACE2, human
DC-SIGN and DC-SIGNL were also shown to be able to
enhance SARS-CoV infection by a non-receptor mecha-
nism [35,36]. However, the influence of residue 743 on
potential interaction between S protein and DC-SIGN or
DC-SIGNL remains unknown. On the other hand, of the
four positively selected sites, two variants L609A and
V765A, were observed in most 04-pcSARS-CoVs, but not
in 03-pcSARS-CoVs, suggesting that they may contribute
to viral adaptive evolution from 03-pcSARS-CoV to 04-
pcSARS-CoV.
The sequence comparison between groups of 02–04 inter-
species epidemic and 03-early-mid epidemic allowed us
to find additional three special substitutions (T1079C,
C1460G and T1994C), which lead to three replacement
(F360S, T487S and L665S) (Fig. 2). Of particular impor-
tance was that all three sites were monomorphic for serine
in the 02–04 interspecies epidemic group, and utterly
Amino acid variations of 45 S proteins Figure 2
Amino acid variations of 45 S proteins. The amino acid 
sequence of CUHK-SU10 strain isolated from 03-late epi-
demic group was used as the reference sequence. The shad-
ows represent the sites or residues under positive selection 
with posterior probability ≥ 0.9. The red sashes highlight 
three special sites where amino acids were replaced and 
fixed in all 03 human strains, suggesting selective sweep act-
ing on the S gene.BMC Microbiology 2006, 6:88 http://www.biomedcentral.com/1471-2180/6/88
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monomorphic for phenylalanine at site 360, threonine at
487 and leucine at 665 in the 03-human epidemic group
(including 03-early-mid and 03-late phases) (Fig. 2). Pre-
vious studies revealed that the replacement T487S benefits
the receptor switch of SARS-CoVs from palm civets to
human [11,23,32]. However, both Codeml program and
DataMonkey package did not detect positive selection on
this site. Therefore, the best explanation should be that
the selective sweep also drives the adaptive evolution of S
gene from animals to humans, despite of little experimen-
tal evidence supporting the advantageous mutations in
sites 360 and 665.
After breaking through the interspecies receptor barrier,
SARS-CoV spread quickly among human hosts and
formed the 03-early-mid epidemic group, a very impor-
tant period for viral adaptation to human host. During
this stage, four major sites (75, 239, 778 and 1163) of S
protein were identified under positive selection. Among
them, sites 778 and 1163 were located in the S2 domain
of S protein, suggesting that they should associate with
membrane fusion, less probability with receptor recogni-
tion [11,23]. The S2 domain contains two highly con-
served heptad repeats HP1 and HP2, both of them form a
six-helix bundle structure via hydrophobic interaction,
facilitating membrane fusion [12,31]. At site 1163 of HR2
region, the positively charged residue lysine replaced the
negatively charged residue glutamic acid in 03-early-mid
epidemic group, suggesting that residue lysine may be
advantageous for S protein adaptation to human cellular
receptors. The antiviral research showed that active pep-
tide (residues 1161–1180) with residue1163E derived
from animal virus possesses less inhibitory activity against
human SARS-CoVs than its human virus counterpart of
1163K [34], which supports the view that the substitution
K1163E contributes to adaptation of SARS-CoV to human
cellular receptors. On the other hand, a strong neutraliz-
ing epitope containing residues 1055–1192 also impli-
cated the possible role of residue 1163 in induction of
neutralizing antibodies despite of little evidence available
for its action on antibody escape [37,38]. As for residue
778, uncharged amino acid tyrosine was fixed in the 03-
late epidemic group by replacing the negatively charged
residue aspartic acid. The importance of residue 778 can-
not be assessed until further site-directed mutagenesis
research is conducted. With respect to residues 75 and
239, they are unlikely to participate in the viral adaptation
process due to their location outside RBD and S2 domain
regions.
Conclusion
A total of 12 sites (75, 239, 244, 311, 479, 609, 613, 743,
765, 778, 1148 and 1163) in S protein were detected
under positive selective pressure. Among them, 8 sites are
exposed on the surface of S protein. It was also found that
the S protein of SARS-CoV experiences variable positive
selective pressures before reaching stabilization, and the
positively selected sites are changeable in different epi-
demic groups. More importantly, a larger proportion of
positively selected sites identified in 02–04 interspecies
epidemic group was located in RBD region of S protein,
suggesting that receptor binding function is predominant
at this stage. On the other hand, more positively selected
sites were located in HR1–HR2 region in 03-early-mid
epidemic group, suggesting that the membrane fusion
function becomes a major task in association with posi-
tive selection at this period. The variation of positive selec-
tive pressures and positively selected sites of S protein
provide a valuable evidence for understanding the molec-
ular adaptation of S protein from animals to humans.
Methods
Sequences
A total of 102 Spike (S) gene sequences of SARS-CoVs and
SARS-like-CoVs from human and animals were retrieved
from the GenBank (Table S1, see additional file 2).
Among them, 100 S gene sequences were obtained from
five previously classified epidemic phases: 02–03, 03-
early, 03-middle, 03-late and 03–04 epidemic phases,
which represent the SARS outbreak sequence from later
2002 to early 2004 [7,14]. The 02–03 epidemic phase
contained SARS-like-CoV sequences from animals (03-
pcSARS-CoV) [6]. The strains of 03-early, 03-middle and
03-late phases were isolated from human (03-huSARS-
CoV). The 03–04 epidemic phase represented the re-emer-
gence of SARS in human patients (04-huSARS-CoV) and
palm civets (04-pcSARS-CoV) [7]. The other two S
sequences of SARS-like-CoVs isolated from bats were used
as the outgroup of phylogenetic tree [39,40].
Phylogenetic analysis, tree construction and 
recombination analysis
After deletion of identical sequences, only 45 distinctive
sequences out of 100 S sequences were used for phyloge-
netic analysis (Table S1, see additional file 2). They were
aligned together with two outgroup sequences using
CLUSTAL × (Ver. 1.83) [41]. The phylogenetic tree of S
gene was obtained by using ML (maximum likelihood)
(PHYML v2.4.4) [42] and NJ (neighbor-joining) (MEGA
3.0) [43] methods, and the reliability of the trees was eval-
uated by the bootstrap method with 1,000 replications.
The dN/dS value was used to detect positive selection. Since
recombination of genes can result in artificially high dN/dS
values and a false detection of positive selection [18,19],
the SimPlot Version 3.5.1 [44] was applied to determine
whether the recombination occurs in S gene of SARS-CoV.
Re-classification of SARS epidemic phases
The outbreak of SARS was previously divided into five epi-
demic phases: 02–03 epidemic, 03-early, 03-middle, 03-BMC Microbiology 2006, 6:88 http://www.biomedcentral.com/1471-2180/6/88
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late, and 03–04 epidemic phases based on the epidemio-
logical investigation [7,14]. The tree topology showed
that isolates from the 02–03 epidemic, 03-human epi-
demic and 03–04 epidemic phases formed a mono-
phyletic clade, respectively (Fig. 1) [7]. The clades formed
by 03-pcSARS-CoVs and 04-pcSARS-CoVs clustered
together, diverging from the clade formed by 03-huSARS-
CoVs, which have been demonstrated being responsible
for transmission of SARS-CoVs from animals such as palm
civets to human [6,7,14]. These suggested that the origin
of 03-huSARS-CoVs should be a virus strain, which was
prevalence in palm civets or other animals before Novem-
ber 2002, but different from both 03-pcSARS-CoV and 04-
pcSARS-CoV [6,7,25].
Because the 02–03 epidemic phase included SARS-CoV
sequences from animals (palm civets and a raccoon dog)
and the 03–04 epidemic phase contained 04-huSARS-
CoV and 04-pcSARS-CoV, they should be at least partially
reflect the course of viral interspecies transmission. In
order to more realistically detect the adaptive evolution of
S genes in interspecies transmission, we merged 02–03
and 03–04 epidemic phases into a unique epidemic
group: 02–04 interspecies epidemic group, representing
the course of SARS-CoV interspecies transmission. With
respect to 03-human epidemic, it was divided into three
phases in the previous studies. In the current study, it
formed a monophyletic clade in phylogenetic tree with a
low bootstrap value (41%) support (Fig. 1). In fact, the
sequences from 03-early and 03-middle phases clustered
together, and did not split each other. In addition, pair-
wise comparison of S gene sequences demonstrated that
03-early and 03-middle phases under positive selection,
suggesting that both phases associate with the adaptation
to human receptor [14]. On the other hand, the 03-late
epidemic phase experienced a longer epidemic time
(more than four months) than the sum of 03-early and
03-middle epidemic phases (about three months), and
showed a lower sequence divergence [14]. We therefore
divided 03-human epidemic into two groups: 03-early-
mid and 03-late epidemic groups according to the epide-
miological investigation and their epidemic time. Thus,
the evolutionary process of S proteins during the whole
SARS epidemic was simplified into three epidemic groups:
02–04 interspecies, 03-early-mid and 03-late epidemic
groups in the present study (Fig. 1). Each group might rep-
resent a unique epidemic phase in the whole SARS out-
break including initial animal-to-human transmission
phase, adaptation to human receptor phase and subse-
quent lineage fixation phase, respectively.
Analysis of the adaptive evolution and identification of 
positively selected sites
The program Codeml implemented in the PAML 3.14 b
software package was used to investigate the adaptive evo-
lution of S protein [45]. A total of 45 aligned S gene
sequences, isolated from the different epidemic groups,
were selected to test whether they were under positive
selection in the whole outbreak. Six models of codon sub-
stitution, M0 (one-ratio), M1a (NearlyNeutral), M2a
(PositiveSelection), M3 (discrete), M7 (beta), and M8
(beta and ω) were used in the analysis [46]. M0 assumes
that all sites have the same ω ratio. M1a assumes two
classes of sites in proteins in proportions p0 and p1 (1 –
p0) with 0 < ω0 < 1 (purifying selection) and ω1 = 1 (neu-
tral sites). M2a adds a proportion (p2) to account for a
class of sites where w2 is estimated from the data and can
be > 1. M3 uses a general discrete distribution with three
site classes, with the proportions (p0, p1 and p2) and the
ω ratios (ω0, ω1 and ω2) estimated from the data. M7
assumes a beta distribution (p, q) for 10 different ω ratios
in the interval (0, 1). M8 adds an extra class of sites with
positive selection (ω > 1) to the beta (M7) model [46,47].
Therefore, the null models M0, M1a and M7 fix the ω
ratios between 0 and 1, and do not allow the presence of
positively selected sites. The alternative models M2a, M3
and M8 account for positive selection by using parame-
ters, which estimate ω greater than 1, and allow for the
variable ω along codon sequence.
Likelihood ratio test (LRT) [48] was performed for detect-
ing the presence of positively selected sites by comparing
the models which do not allow for positive selection with
the models which allow for positive selection. The LRT
was performed by taking twice the difference in log likeli-
hood between nested models, and testing for significance
using the χ2 distribution with the degrees of freedom (d.f.)
equivalent to the difference in the number of parameters
between models. If the LRT is significant, positive selec-
tion is inferred. In the present study, three LRTs (M0 vs.
M3, M1a vs. M2a, and M7 vs. M8) were used to detect pos-
itive selection. The Bayes empirical Bayes (BEB) approach
implemented in M2a and M8 was used to determine the
positively selected sites by calculating the posterior prob-
abilities (p) of ω classes for each site [47]. The sites with
high posterior probabilities (p > 0.95) coming from the
class with ω > 1 were believed to be under positive selec-
tion [46].
Because positive selection on S gene was detected during
the whole SARS outbreak, the sequences from three differ-
ent epidemic groups were also analyzed using Codeml
program to further specify the epidemic group in which
positive selection occurred and the exact location of posi-
tively selected sites in S proteins. To further confirm posi-
tively selected sites identified by using program Codeml,
three additional methods including single likelihood
ancestor counting (SLAC), fixed effects likelihood (FEL),
and random effects (REL) as implemented in the on-line
DataMonkey package were employed [49,50]. To detectBMC Microbiology 2006, 6:88 http://www.biomedcentral.com/1471-2180/6/88
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positively selected sites, the 0.1 level of significance was
used for both SLAC and FEL, and default significant level
of Bayes factor > 50 was used for REL. In the process of
analysis, the results of three epidemic groups were
obtained. However, as a result of the large amount of data,
which exceed the acceptability of DataMonkey package,
we failed to obtain the results of 45 sequences, which rep-
resent the whole SARS outbreak. In order to reduce the
influence of type-I error rate (false discovery rate) [51], the
sites identified under positive selection at significant level
by both Codeml program and REL methods in DataMon-
key package were used to investigate their lineage fixation
for the adaptation of SARS-CoV S protein from animals to
human hosts.
Statistical analysis
The statistical analysis for the comparison of positively
selected sites between different groups was performed
using one-sided χ2 test or one-sided Fisher's exact test in
GraphPad Prism version 4.03 for Windows demo.
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